What is PepGen?
Founded in 2018 and based in Cambridge, Massachusetts, PepGen is dedicated to advancing the next generation of oligonucleotide therapeutics. The company's strategic focus is on developing innovative treatments for debilitating neuromuscular and neurologic conditions, aiming to transform patient outcomes in these challenging disease areas. This latest round of financing is expected to fuel the advancement of its therapeutic pipeline and clinical development programs.
How much funding has PepGen raised?
PepGen has raised a total of $56.3M across 2 funding rounds:
Series A
$45M
Unspecified
$11.3M
Series A (2020): $45M with participation from Oxford University, RA Capital Management LP, CureDuchenne, and Oxford Sciences Enterprises
Unspecified (2021): $11.3M led by Oxford Sciences Enterprises, Viking Global Investors, RA Capital Management, and CureDuchenne
Key Investors in PepGen
Oxford Sciences Enterprises
Oxford Science Enterprises is an independent investment company partnered with the University of Oxford, focused on building transformational businesses from university research.
Viking Global Investors
Viking Global Investors is a global investment firm specializing in research-intensive, long-term focused investments across various industries and geographies.
CureDuchenne
CureDuchenne is a nonprofit organization that funds innovative research and supports the development of treatments for Duchenne muscular dystrophy through a venture philanthropy model.
What's next for PepGen?
The substantial enterprise-level funding PepGen has garnered, including its recent strategic investment, positions the company for accelerated growth and pipeline expansion. This capital infusion is anticipated to support the progression of its oligonucleotide-based therapies through critical clinical trial phases, potentially bringing novel treatment options to patients suffering from severe neuromuscular and neurologic diseases. The company's trajectory suggests a strong emphasis on research and development, aiming to solidify its position as a leader in oligonucleotide therapeutics.
See full PepGen company page
